ABSTRACT
Treatment of many infectious diseases is under threat from drug resistance. Understanding the mechanisms of resistance is as high a priority as the development of new drugs. We have investigated the basis for cross-resistance between the diamidine and melaminophenyl arsenical classes of drugs in African trypanosomes. We induced high levels of pentamidine resistance in a line without the tbat1 gene that encodes the P2 transporter previously implicated in drug uptake. We isolated independent clones that displayed very considerable cross-resistance with melarsen oxide but not phenylarsine oxide and reduced uptake of \[^{3}H\]pentamidine. In particular, the high-affinity pentamidine transporter (HAPT1) activity was absent in the pentamidine-adapted lines, whereas the low affinity pentamidine transport (LAPT1) activity was unchanged. The parental tbat\(^{-1/2}\) line was sensitive to lysis by melarsen oxide and this process was inhibited by low concentrations of pentamidine, indicating the involvement of HAPT1. This pentamidine-inhibit-
able lysis was absent in the adapted line KO-B48. Likewise, uptake of the fluorescent diamidine 4,6-diamidino-2-phenylin-
dole dihydrochloride was much delayed in live KO-B48 cells and insensitive to competition with up to 10 \(\mu\)M pentamidine. No overexpression of the \textit{Trypanosoma brucei brucei} ATP-binding cassette transporter TbmRPA could be detected in KO-B48. We also show that a laboratory line of \textit{Trypanosoma brucei gambiense}, adapted to high levels of resistance for the melaminophenyl arsenical drug melarsamine hydrochloride (Cymelarsan), had similarly lost Tbat1 and Hapt1 activity while retaining Lap1 activity. It seems therefore that selection for resistance to either pentamidine or arsenical drugs can result in a similar phenotype of reduced drug accumulation, explaining the occurrence of cross-resistance.

**Trypanosoma brucei** subspp. are protozoan parasites that cause human African trypanosomiasis (i.e., sleeping sickness) and the corresponding veterinary condition in livestock. Treatment of both the human and livestock diseases depends on a very small set of mostly very old drugs. The first-line treatment for the late stage of both West African and East African human African trypanosomiasis is malar-
soprol, an organoarsenic compound of the melaminophenyl arsenical class, introduced in 1949 (Jannin and Cattand, 2004). A similar but water-soluble melaminophenyl arsenical, melarsamine hydrochloride (Cymelarsan), is increasingly used for animal trypanosomiasis. Early-stage West Af-
rican sleeping sickness is routinely treated with the diamidine drug pentamidine, introduced in 1937 (Jannin and Cattand, 2004). The corresponding widely used veterinary diamidine is diminazene aceturate (Berenil). The only new trypanocide to be developed in recent decades, DB75, is also a diamidine and currently in clinical trials as an orally avail-
able prodrug.

It has been known for decades that cross-resistance be-
tween melaminophenyl arsenicals and diamidine drugs sometimes occurs (Fulton and Grant, 1955; Williamson and Rollo, 1959), but cross-resistance patterns can be unpredict-
able (Williamson, 1970). Kaminsky and Mäser (2000) distin-

**ABBREVIATIONS:** LAPT1, low-affinity pentamidine transporter; HAPT1, high-affinity pentamidine transporter; ABC, ATP-binding cassette transporter; Tbat1, \textit{Trypanosoma brucei} adenosine transporter 1; MRP, multidrug resistance protein A; TbmRPA, \textit{Trypanosoma brucei} multidrug resistance protein A; DAPI, 4,6-diamidino-2-phenylindole dihydrochloride; DIC, differential interference contrast; TES, Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; RT, room temperature; PFR, paralflagellar rod protein; WT, wild-type.
guished six distinct resistance profiles in *Trypanosoma brucei* laboratory strains and field isolates, presumably an indication that multiple factors determine (the level of) resistance to the various drugs. They also noted that some resistance profiles seem to be associated with either field or laboratory-induced resistance.

Some progress has been made in understanding drug resistance mechanisms in trypanosomes. The important role of the *T. brucei* AT1/P2 purine transporter in the accumulation of melaminophenyl arsenical compounds and diamidines is now well understood (Carter and Fairlamb, 1993; Mäser et al., 1999; De Koning, 2001a; Delespaux and De Koning, 2007). The loss of TbAT1/P2 alone was shown to be sufficient for high levels of diminazene acetate resistance in *T. brucei brucei* and *Trypanosoma evansi* (De Koning et al., 2004; Witola et al., 2004). However, the deletion of the *TbaT1* gene produced only minor loss of sensitivity to pentamidine and melaminophenyl arsenicals (Matovu et al., 2003). Thus, the action of some diamidines relies (almost) exclusively on TbAT1/P2 for access to intracellular targets, whereas other diamidines, as well as melaminophenyl arsenicals, have at least one additional route of entry.

We have shown previously that adenosine-insensitive uptake of [3H]pentamidine in *T. brucei brucei* is mediated by two discrete transport activities: a low-affinity pentamidine transporter [LAPT1 (De Koning and Jarvis, 2001)] and a high-affinity pentamidine transporter [HAPT1 (De Koning, 2001b)]. Although this seems to explain why clinical pentamidine resistance has not established itself, despite the many decades of intensive use (for review, see Bray et al., 2003), it was not clear whether high levels of pentamidine resistance might ensue with the consecutive loss of TbAT1/P2 and either HAPT1 or LAPT1. Nor is it yet clear why the *tbat1*<sup>-/-</sup> line did not display an appreciable level of resistance to melaminophenyl arsenical drugs (Matovu et al., 2003). It has been argued that higher levels of arsenical resistance in trypanosomes could be the result of the (over)expression of an ABC-type transporter of the multidrug resistance type, TbMRPA. Overexpression of this transporter in *T. brucei brucei* does induce 10-fold resistance to melarsoprol in vitro (Shahi et al., 2002). Arsenical resistance attributed to loss of TbAT1/P2 and overexpression of TbMRPA were shown to be additive (Lüscher et al., 2006). However, TbMRPA overexpression did not lead to arsenical resistance in vivo, and TbMRPA overexpression could not be demonstrated in melarsoprol-resistant trypanosome isolates from patients with sleeping sickness (Alibu et al., 2006).

In the current article, we address the outstanding questions concerning diamidine and arsenical resistance using *Trypanosoma brucei* lines adapted to high levels of pentamidine and cross-resistant to melaminophenyl arsenicals. We now provide a model for the biochemical basis of cross-resistance between melaminophenyl arsenicals and the diamidines. The model predicts that HAPT1, together with TbAT1, may be a key determinant for arsenical resistance in African trypanosomes, providing a hypothesis that should now be validated on clinical isolates from patients refractory to melarsoprol.

**Materials and Methods**

**Trypanosomes and Cultures.** Growth of bloodstream trypanosomes in culture was performed using HMI-9 medium (BioSera Ltd., East Sussex, UK) (Hirumi and Hirumi, 1989) supplemented with 2 mM β-mercaptoethanol and 10% fetal bovine serum at 37°C in a 5% CO₂ atmosphere. For transport assays, trypanosomes were grown in adult female Wistar rats and isolated from infected blood as described previously (De Koning and Jarvis, 1997). The cloned *Trypanosoma brucei gambiense* type 2 stock STIB 386 and the derived melasarmine hydrochloride-resistant clone 386MelCy<sup>β</sup> (hereafter called 386Ms and 386Mr) were a kind gift of Professor C.M.R. Turner (University of Glasgow). The adaptation of 386Ms to high levels of melasarmine hydrochloride has been described elsewhere (Scott et al., 1996). The *T. brucei* clone s427 (M/AT 1.2/221) was used to derive the *tbat1*<sup>-/-</sup> line (Matovu et al., 2003) and the pentamidine-adapted clonal line WT-D24. *tbat1*<sup>-/-</sup> was also adapted to higher levels of pentamidine resistance, generating the clonal lines KO-B6, KO-D6, KO-B48, and KO-D48. Clonal populations were generated by limiting dilution. Cell densities were assessed using a hemocytometer and phase-contrast microscope. The New York line of *T. brucei brucei* (Wirtz et al., 1999) and the derived MRPA overexpressing line NY-mrpa have been described previously (Lüscher et al., 2006). Overexpression was induced (NY-mrpa<sup>+</sup>) or repressed (NY-mrpa<sup>-</sup>) by the inclusion or omission, respectively, of 1 µg/ml tetracycline in the culture medium.

**Transport Assays.** Transport assays were performed exactly as described previously (Wallace et al., 2002). In brief, trypanosomes were isolated from blood taken from infected Wistar rats by DEAE-52 (Whatman, Maidstone, UK) anion exchange chromatography, washed into assay buffer, and resuspended at ~2 × 10<sup>7</sup> cells/ml at room temperature. In a minority of cases, trypanosomes for transport assays were cultured in complete HMI-9 medium. Aliquots (100 µl) of bloodstream trypanosomes in assay buffer were mixed with an equal volume of buffer containing radiolabel and sometimes inhibitor, at twice the final concentration, initiating transport. Transport was terminated by the addition of 1 ml of ice-cold buffer containing unlabeled permeant at a saturating concentration (2 mM for pentamidine) followed by rapid centrifugation through an oil layer, separating cells from radiolabel not internalized. Transport values are expressed as picomoles per 10<sup>7</sup> cells per second.

**Drug Sensitivity Assays.** Drug sensitivity was determined using the dye resazurin (Alamar blue) exactly as described previously (Wallace et al., 2002) in a protocol adapted from Ráz et al. (1997). In brief, drugs were serially diluted in 100 µl of complete HMI-9 media across a 96-well microtiter plate. Unless limited by solubility, the top drug concentration used was 1 mM. Cultures of bloodstream-form trypanosomes were grown to a maximum density of 2 × 10<sup>8</sup> cells/ml and diluted to 2 × 10<sup>4</sup> cells/ml with complete HMI-9 medium, of which 100 µl was added to all wells. Plates were then incubated for 48 h at 37°C in a 5% CO₂ atmosphere, before the addition of 20 µl of 5 mM resazurin (Sigma, St. Louis, MO) solution in PBS, pH 7.4. Plates were incubated for an additional 24 h at 37°C, before fluorescence was measured using a LS 55 luminescence spectrometer (λ<sub>em</sub> = 530 nm, λ<sub>ex</sub> = 590 nm; PerkinElmer Life and Analytical Sciences, Boston, MA).

**Fluorescence Microscopy.** *T. brucei* were pelleted (600g, 10 min at room temperature) before being resuspended in fresh HMI-9 media containing 10 µM concentrations of stilbamidine, 4,6-diamidino-2-phenylindole dihydrochloride (DAPI), DB75, or Hoechst 33342 solution at room temperature and assessed by fluorescence microscopy. Glass slides of the culture were prepared and examined using differential interference contrast (DIC) and fluorescence microscopy (λ<sub>ex</sub> = 365 nm; λ<sub>em</sub> = 445 nm) on an Axioskop 2 imaging microscope (Carl Zeiss GmbH, Jena, Germany) using Velocity v. 3.7 software (Improvision, Coventry, UK). Where necessary, parasites were fixed by incubating in PBS containing 2.5% glutaraldehyde for 20 min. Cells were then washed in 0.05 M glycine in PBS before being mounted on slides.

**Lysis Assays.** The lysis assays were performed essentially as described by Fairlamb et al. (1992), using bloodstream trypanosomes of *tbat1*<sup>-/-</sup> and KO-B48 grown in vitro. They were washed and...
resuspended in fresh HMI-9 medium with 10% fetal calf serum at
−2 × 10^7 cells/ml, which was transferred to 1-ml cuvettes. Absorp-
tion was monitored, at 750 nm, at 30-s intervals. Melarsen oxide or
phenylarsine oxide were added after 15 min to allow the recording of
a short baseline. Up to 16 cultures were monitored simultaneously,
phenylarsine oxide were added after 15 min to allow the recording of
the experiment.

Preparation of Plasma Membrane Protein-Enriched Fractions. bat1^−/−
and KO-B48 plasma membrane-enriched samples were generated by a modification of the procedure described by
Voorheis et al. (1979). In brief, bloodstream-form trypanosomes were
cultured in vivo in adult female Wistar rats infected by i.p. injection.
Blood was collected at peak parasitemia under terminal anesthesia, and
parasites were isolated as for transport assays. Cells were then
omotochially stressed by addition of water (at 4°C), and swelling was
monitored by phase-contrast microscopy until a spherical morphol-
y had been achieved. Cells were then homogenized in an AO Cell
Disruptor (Stansted Fluid Power, Stansted, UK), in the presence of
protease inhibitors. The homogenate was then returned to a normal
osmotic potential through the addition of 3 M KCl to a final concen-
tration of 140 μM, before pelleting the cells. Cells were then treated
with 240 units of DNase in TES buffer (20 mM TES, 150 mM KCl, 5
mM MgCl2, and 1 mM 2-mercaptoethanol, pH 7.4), for 5 min at 20°C.
The reaction was terminated by the addition of 5 volumes of TES
buffer (20 mM TES, 150 mM KCl, 1 mM EDTA, and 1 mM 2-mer-
captoethanol, pH 7.4). Cells were pelleted and then re-suspended
in 40% sucrose before being layered on a linear 40 to 60% sucrose
gradient (in TES buffer). Samples were then centrifuged for
3 h at 70,000g on a SW28 rotor (Beckman Coulter, Fullerton, CA). The
most prominent dense white band, corresponding to the plasma
membrane fraction, was isolated and washed twice in TES buffer
and then resuspended without sucrose, before being aliquoted and stored in TES buffer at
−80°C. All procedures were performed at 4°C unless otherwise
stated.

Western Blotting. Samples for Western blotting were plasma
membrane preparations (described under Preparation of Plasma
Membrane Protein-Enriched Fractions) or whole-cell protein extracts
prepared from 2 × 10^7 cells, washed in PBS, and flash-frozen in dry
ice/ethanol. Samples solubilized in standard Laemmli buffer (60°C
for 10 min) were loaded onto a 10% SDS polyacrylamide gel and run
until the bromphenol blue dye front reached the end of the gel.
Proteins were then transferred onto a nitrocellulose membrane (Hy-
bond ECL, GE Healthcare, Little Chalfont, Buckinghamshire, UK)
at 4°C in MeOH-Tris-glycine buffer. Blots were incubated in blocking
solution (TBS-Tween 20 containing 5% milk powder) for 1 h at room
temperature (RT). Primary antibodies raised to MRPA, kindly pro-
vided by Christine Clayton, University of Heidelberg, were diluted
1:500 in blocking solution (TBS-Tween 20 containing 5% milk powder) and
incubated with the blot for 1.5 h at RT. Unbound/excess antibodies were removed by washing in TBS-Tween 20 (2 × 10 min)
and then TBS (10 min). Secondary peroxidase-conjugated anti-
mouse immunoglobulin antibodies (Dako Denmark A/S, Glostrup,
Denmark) were then incubated with the blot (diluted 1:1000) in
blocking solution at RT for 1 h. Unbound secondary antibodies were
removed by washing (as with primary antibodies). Bound antibodies
were detected using the ECL Plus western blotting detection System
(GE Healthcare) according to the manufacturer’s instructions. For
normalization, the blot was stripped and reprobed using a polyclonal
antiserum against paraflagellar rod protein (PFR; diluted 1:1000) as
described previously (Schlaeppi et al., 1989) and a secondary perox-
idase-conjugated anti-rat immunoglobulin antibody (diluted
1:10,000) (Dako Denmark A/S).

Results

Induction of High-Level Pentamidine Resistance in T. brucei brucei. To maximize the likelihood of the successful
formation of drug-resistant lines, we applied selection
pressure to four separate cultures from each of the two pa-
rental strains, s427 (WT) and the isogenic clone
T. brucei brucei.

Infectivity of Pentamidine-Adapted T. brucei brucei Lines in Mice. Groups of three to five ICR mice (Harlan UK Ltd., Bicester,
Oxon, UK) were infected with 10^4 trypanosomes in 200 μl of full
HMI-9/fetal calf serum culture medium by i.p. injection. In some
cases, the mice had been immunosuppressed by treatment with
cyclophosphamide (200 mg/kg cyclophosphamide in water, injected
i.p.) 24 h before infection. Parasitemia was estimated daily by the
rapid “matching” method (Herbert and Lumsden, 1976) from exam-
inations of wet blood films on microscope slides, collected by tail
prick, using a phase-contrast microscope. Mice reaching a para-
sitemia of antilog 8.4 (2.5 × 10^8 cells/ml blood) or over were eutha-
nized by inhalation of a rising concentration of CO_2.
During each round of selection, it was observed that the initial acquisition of resistance in the presence of drug was associated with a reduced growth phenotype (Fig. 1B), in terms of both doubling time and maximum cell density. For all the lines eventually selected, this was reversed to a parental growth phenotype by maintaining the same selection pressure for an additional period of time (Fig. 1C). Once the resistance phenotype was well established, removal of pentamidine from the media had no effect on growth, and the resistance phenotype was stable for at least 3 months in the absence of drug pressure.

**Cross-Resistance Profile of KO-B48 and KO-D48.** We have previously reported the cross-resistance phenotype of the \( \text{tbat1}^{-/-} \) strain (Matovu et al., 2003), which displayed high levels of resistance to diminazene but only minor loss of sensitivity to pentamidine and the melaminophenyl arsenical drugs melarsoprol, melarsen oxide, and melarsamine hydrochloride. Using the same protocol based on the reduction of the dye Alamar blue (resazurin), we have repeated these experiments with WT, \( \text{tbat1}^{-/-} \), KO-B48, and KO-D48 in parallel. The results are presented as a series of bar graphs in Fig. 2. The phenotypes of KO-B48 and KO-D48 were very similar. Compared with the WT strain, a large increase in pentamidine resistance was observed, reaching an average 130- and 82-fold resistance in KO-B48 and KO-D48, respectively (\( n = 8 \); Fig. 3). Resistance to melarsen oxide was also markedly increased in KO-B48 and KO-D48 (15.4- and 10.7-fold, respectively, relative to WT; Fig. 2B). Sensitivity to propamidine and stilbamidine, already reduced in the KO strain, was modestly decreased further in KO-B48 and KO-D48 (Fig. 2, C and D), whereas resistance to diminazene aceturate was not further increased in the pentamidine resistant lines (Fig. 2E). Sensitivity to phenylarsine oxide, which freely diffuses across membranes, was identical in all the lines (Fig. 2E), showing that the resistance phenotype was most likely associated with changes in drug uptake. A table with exact sensitivities of all four trypanosome lines to all six drugs is included as on-line only Supplementary Data.

**Pentamidine Transport in Pentamidine-Resistant Trypanosome Lines.** Transport of 0.5 \( \mu \text{M} \) \( ^{3}\text{H} \)pentamidine was drastically reduced in both KO-B48 and KO-D48, compared with the parental \( \text{tbat1}^{-/-} \) line (Fig. 4A,B), by 74 and 68%, respectively. To exclude the possibility that culture conditions had somehow played a role in the reduced uptake rates, the experiment was repeated with \( \text{tbat1}^{-/-} \) and KO-B48 cells grown in Wistar rats (Fig. 4C). The result clearly demonstrates that pentamidine transport in the adapted lines is severely impaired yet remains saturable (Figs. 4C and 5). We also confirmed that transport in KO-B48 was not generally impaired, using \( ^{3}\text{H} \)2-deoxyglucose. Uptake of \( ^{3}\text{H} \)2-deoxyglucose by KO and KO-B48 cells was determined in three independent experiments, each performed in triplicate, and found to be linear over 30 min, completely saturated by 10 mM 2-deoxyglucose, and not significantly different between the two trypanosome lines (Supplementary Data Fig. 1). Pentamidine transport in the \( \text{tbat1}^{-/-} \) strain is mediated by two transporters, HAPT1 and LAPT1 (Matovu et al., 2003). To determine whether one or both of these transporters were affected in the highly resistant line KO-B48, a series of transport assays was performed at 15 nM \( ^{3}\text{H} \)pentamidine. This very low concentration of radiolabel is necessary to

![Fig. 2. Drug sensitivity profile of four T. brucei brucei clones. A, pentamidine. B, melarsen oxide. C, propamidine. D, stilbamidine. E, diminazene aceturate. F, phenylarsine oxide (PAO). Error bars indicate S.E. All values are the average of between 3 and 11 determinations. A table with the exact values and number of replicates is available as on-line only supplementary material.](https://doi.org/10.1093/molpharm/asp181.71001)
avoid saturating HAPT1 and to obtain a biphasic inhibition curve showing both the high-affinity (but low-capacity) HAPT1 activity and the low-affinity (but high-capacity) LAPT1 activity in the WT s427 and tbat1−/− strains (De Koning, 2001b; Matovu et al., 2003). The presence of a high-affinity pentamidine transport activity could not be confirmed in KO-B48: it was either absent altogether or its transport capacity was very significantly reduced (Fig. 5A), although pentamidine transport was clearly biphasic in the control WT strain (Fig. 5B). In contrast, the low-affinity transporter LAPT1 seemed completely unchanged compared with parental strains (Fig. 5, A and C): \( K_m \) and \( V_{\text{max}} \) values were identical to those previously reported for the parental line s427 (Table 1).

Arsenical-Induced Lysis in tbat1−/− Is Mediated by HAPT1 and Absent in KO-B48. Lysis of trypanosomes, induced by arsenical drugs, can be monitored spectroscopically at 750 nm (Fairlamb et al., 1992) and was used to induced lysis can be discerned and displays the pharmacological profile of HAPT1 (Matovu et al., 2003). The results depicted in Fig. 6A confirm this observation. Although melaminophenyl arsenicals act more slowly on \( T. \) brucei \( \text{brucei} \) principally through P2 (Carter and Fairlamb, 1993). We have previously used this technique to show that in \( \text{brucei} \) cells, a secondary, slower phase of melarsen oxide-induced lysis can be discerned and displays the pharmacological profile of HAPT1 (Matovu et al., 2003). The results depicted in Fig. 6A confirm this observation. Although melaminophenyl arsenicals act more slowly on \( \text{brucei} \) than on WT cells (Matovu et al., 2003), 10 \( \mu \)M melarsen oxide induced cell lysis in \( \text{brucei} \) cells in approximately 50 min (trace a), but coadministration of as little as 1 \( \mu \)M pentamidine with 10 \( \mu \)M melarsen oxide substantially delayed cell lysis (trace b). In contrast, the same concentration of pentamidine had no influence on lysis induced by phenylarsine oxide (traces c and d), which rapidly diffuses across membranes (Carter and Fairlamb, 1993).

In KO-B48 cells, melarsen oxide-induced lysis is already much delayed compared with \( \text{brucei} \) cells (trace a), and 1 \( \mu \)M pentamidine has no further effect (trace b), demonstrating the absence of HAPT1 activity. Again, coinoculation with 1 \( \mu \)M pentamidine had no effect on lysis induced by phenylarsine oxide (traces c and d), and the timing of phenylarsine-induced lysis was identical in both strains.

Assessment of Pentamidine Transporters Using Fluorescent Microscopy. The rate of entry of fluorescent diamidines, monitored by fluorescence-activated cell sorting or fluorescence microscopy, can be used as a probe to investigate changes in membrane permeability and cross-resistance patterns (Frommel and Balber, 1987; Stewart et al., 2005). Like Frommel and Balber (1987), we used 4,6-diaminid-2-phenylindole dihydrochloride as a fluorescent substitute for pentamidine. This was possible given the fact that DAPI displays considerable affinity for all three pentamidine transporters. \( K_i \) values are \( 0.67 \pm 0.12 \) \( \mu \)M (TbAT1/P2, \( n = 3 \)), \( 26 \pm 6 \) \( \mu \)M (HAPT1, \( n = 3 \)), and \( 20 \pm 6 \) \( \mu \)M (LAPT1, \( n = 5 \)) (data not shown). The highest affinity was for TbAT1/P2; nonetheless, this transporter did not primarily mediate DAPI transport. Figure 7 shows that the rate of development of fluorescence was not clearly different in live long-slower WT s427 or \( \text{brucei} \) cells. By 5 min, fluorescence was clearly observed, and by 10 min, staining of both nucleus and kinetoplast was very intensive. In contrast, KO-B48 cells showed only faint fluorescence in both organelles after 20 min. Even after 60 min, fluorescence was much less than that observed in the

![Fig. 3. Sensitivity of four T. brucei brucei clones to pentamidine (A) and melarsen oxide (B). Lines used were WT (□), KO, (●), KO-B48 (△), and KO-D48 (○). The data shown is a representative experiment using the Alamar blue method as described under Materials and Methods section. IC_{50} values were calculated by nonlinear regression. Fluorescence is given in arbitrary units on a scale of 0 to 1000. The lowest concentration data point is the “no drug” control.](image-url)

![Fig. 4. Transport of 0.5 \( \mu \)M \[^{3}H\]pentamidine in resistant trypanosome lines. A, uptake of pentamidine by KO-B48 (○) or the parental \( \text{brucei} \) strain (■) grown in culture in the absence of pentamidine pressure and the two strains were assayed simultaneously. Lines were calculated by linear regression. B48, \( r^2 = 0.99 \), slope = 0.027 ± 0.005; \( \text{brucei} \), \( r^2 = 0.99 \), slope = 0.10 ± 0.006. B, uptake of pentamidine by KO-D48 (○) or the parental \( \text{brucei} \) strain (■) grown in culture in the absence of pentamidine pressure and the two strains were assayed simultaneously. Lines were calculated by linear regression. D48, \( r^2 = 0.97 \), slope = 0.038 ± 0.005; \( \text{brucei} \), \( r^2 = 0.99 \), slope = 0.17 ± 0.01. C, uptake of \[^{3}H\]pentamidine by KO-B48 (○) or the parental \( \text{brucei} \) strain (■) grown in Wistar rats, in the presence (open symbols) or absence (filled symbols) of 1 mM nonlabeled pentamidine. Lines were calculated by linear regression. Values in the absence of pentamidine were as follows: B48, \( r^2 = 0.97 \), slope = 0.0032 ± 0.0001; \( \text{brucei} \), \( r^2 = 0.94 \), slope = 0.021 ± 0.002. Pentamidine uptake is expressed as picomoles per 10^7 cells. Symbols represent average of triplicate determinations; error bars are S.E., when not shown fall within the symbol.)
other cell lines at 10 min (Fig. 7). Care was taken to exclude any dead cells from the observations, as they accumulated DAPI very rapidly, presumably as a result of loss of membrane integrity.

It thus seems that the rate of DAPI uptake is much reduced in KO-B48 cells, relative to the parental line bat1<sup>-/-</sup>. To assess whether this was caused by the loss of HAPT1 or LAPT1, the development of fluorescence was again monitored in live KO-B48 cells incubated with DAPI alone or in the presence of either 10 μM pentamidine (saturates HAPT1) or 1 mM pentamidine (saturates both transporters). The results in Fig. 8A show accumulation in live cells at 25, 45, and 60 min of incubation with the fluorophore. It is clear that the lower concentration of pentamidine does not delay the rate of DAPI accumulation compared with the no-drug control, whereas 1 mM pentamidine practically abolishes DAPI fluorescence over 60 min. The P-glycoprotein inhibitor verapamil (50 μM) did not affect the accumulation rate of DAPI (Fig. 8A). Using live, motile trypanosomes does not allow the overlay of DIC and fluorescent images and causes imperfect focus on the fluorescence micrographs. At the termination of the experiment, at 60 min, cells were therefore fixed with glutaraldehyde. The higher quality DIC, fluorescence, and overlay images shown in Fig. 8B confirm the conclusions of the timed/real time experiment depicted in Fig. 8A.

The Drug Efflux Transporter TbMRPA Is Not Over-expressed in KO B-48. To verify whether the cross-resistance phenotype of KO B-48 can be partly explained through the elevated expression of TbMRPA, an ABC transporter of the multidrug resistance (mdr) family, plasma membrane-enriched extracts of bat1<sup>-/-</sup> and KO B-48 were run on one-dimensional SDS polyacrylamide gels and transferred to nitrocellulose for Western blotting with anti-TbMRPA antisera. Protein preparations from tetracycline-induced and noninduced NY-mrpa cells and parental NY trypanosomes were analyzed in parallel as control cells. MRPA was clearly present in NY-mrpa<sup>+</sup> cells but could not be detected in any of the other lines (Fig. 9A). In contrast, the presence of PFR could easily be demonstrated in each of the preparations (Fig. 9B).

Infectivity of the KO-B48 and KO-D48 Lines. During in vivo culturing it was observed that infectivity of both KO-B48 and KO-D48 lines was much reduced compared with WT and bat1<sup>-/-</sup> lines. To assess this systematically, groups of five mice were infected with 10<sup>4</sup> T. brucei brucei organisms from bat1<sup>-/-</sup> and each of the derived pentamidine resistant lines. In both KO-B6 and KO-B48 groups, all mice developed detectable parasitemia within 3 days, which, however, rapidly disappeared. Two mice of the KO-B48 group suffered 1 or 3 subsequent relapses, otherwise, no parasitaemia was detectable in thick blood smears taken daily. No parasitaemia was observed at all in the KO-D6 group, and only one mouse in the KO-D48 group developed a brief, low parasitaemia on day 5. In contrast, the bat1<sup>-/-</sup> line appeared far more virulent. One group of mice was infected with bat1<sup>-/-</sup> cells from a long-term culture. All mice rapidly developed substantial parasitaemia, and two mice had to be euthanized. In the last group, infected with the same number of bat1<sup>-/-</sup> cells from stabilates kept in liquid nitrogen and only briefly brought back into culture, all mice developed massive parasitaemia and were euthanized (four on day 4, one on day 13). To investigate whether the lack of infectivity was innate to the adapted trypanosome lines or dependent on the immune system, groups of immunocompromised mice were infected. As shown in Fig. 10A, all mice infected with bat1<sup>-/-</sup> cells developed similar parasitaemia and were euthanized on day 7. In the KO-B48 and KO-D48 groups (Fig. 10, B and C), all mice similarly established substantial parasitaemia; in all but one mouse in the KO-B48 group, however, these were transient and the mice apparently self-cured.

An Arsenical-Resistant T. brucei gambiense Clone Has Lost ThbAT1 and HAPT1. To assess whether loss of
HAPT1 activity is peculiar to selection with pentamidine, we also assessed [3H]pentamidine transport in a T. brucei gambiense type 2 clone, 386Mr, adapted for high levels of melar- samine hydrochloride resistance in vivo (Scott et al., 1996). The [3H]pentamidine transport profile of the parental line STIB 386Ms, conformed to the same three-transporter model as the earlier characterized T. brucei brucei s427 (De Koning, 2001b; Bray et al., 2003). Using fluorescence microscopy similar to the experiments shown here, it has previously been shown that 386Ms accumulates the diamidine DB99 much more slowly than the parental line (Stewart et al., 2005).

Figure 11A shows that uptake of 0.015 μM [3H]pentamidine was inhibited partly by adenosine, with a K_i value of 1.8 μM, consistent with inhibition of HAPT1 but not LAPT1 (De Koning, 2001b), with a K_i value of 9.0 ± 3.0 μM (n = 3). The third transport activity was evident as inhibited by high concentrations of unlabeled pentamidine but not by propamidine or adenosine, consistent with LAPT1 activity. In contrast to 386Ms, transport of [3H]pentamidine in 386Mr was not sensitive to either adenosine or propamidine (Fig. 11B), showing the absence of TbAT1 and HAPT1 activity in these cells.

The K_m and V_max values of HAPT1 and LAPT1 activities in the T. brucei gambiense lines are listed in Table 1 and are very similar to those determined in WT T. brucei brucei. Table 1 also shows that the V_max of LAPT is not changed in the resistant T. brucei gambiense line, relative to its parental line.

### Discussion

In principle, pentamidine resistance in African trypanosomes could be associated with changes in the intracellular drug target, with reduced uptake of the drug or with active extrusion from the cell by an ABC-type efflux pump.

It has been shown that, in wild-type T. brucei brucei, pentamidine uptake is very rapid and efficient, amounting to a cytosolic concentration corresponding to at least 1 mM, if the drug were to remain unbound (Damper and Patton, 1976). Such an intracellular accumulation of the drug is likely to interfere with multiple vital processes and it has long been hypothesized that resistance would most likely be associated with a reduction in cellular levels (Wang, 1995).

Indeed, different authors (Wang, 1995) have demonstrated various effects of pentamidine on cellular processes. Pentamidine resistance in T. brucei brucei based on acquired mutations in any one target, while impossible to rule out, would thus seem unlikely.

Another potential route to drug resistance is the expression of ABC transporters capable of actively removing the toxic compound from the cell. Strong evidence couples this mechanism to drug resistance in some protozoa, including Plasmodium and Leishmania spp. and Entamoeba histolytica (Légaré et al., 2001; Lopez-Camarillo et al., 2003). In T. brucei, three ABC transporter genes have been identified (Mäser and Kaminsky, 1998). However, in studies with the P-glycoprotein inhibitor verapamil, no evidence could be found for the involvement of such transporters in multidrug resistance in T. brucei brucei, either in vitro or in vivo (Kaminsky and Zweygarth, 1991). Experimental overexpression of the T. brucei brucei ABC transporter TbMRPA

### Table 1

<table>
<thead>
<tr>
<th>Trypanosome Species and Line</th>
<th>HAPT1</th>
<th>LAPT1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K_m</td>
<td>V_max</td>
</tr>
<tr>
<td>T. brucei brucei s427</td>
<td>0.036±0.006</td>
<td>0.0044±0.0004</td>
</tr>
<tr>
<td>that1/+-b</td>
<td>0.029±0.008</td>
<td>N.D.</td>
</tr>
<tr>
<td>KO-B48</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>T. brucei gambiense 386Ms</td>
<td>0.038±0.004</td>
<td>0.0022±0.0008</td>
</tr>
<tr>
<td>386Mr</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

N.D., not detectable.
a Values from De Koning, 2001b.
b IC_{50} values from Matovu et al., 2003.

---

**Fig. 6.** Lysis of trypanosomes induced by 10 μM melarsen oxide. A, strain that1/-. B, strain KO-B48. Melarsen oxide (10 μM) was added after 15 min of recording, as 50 μl [200 μM] in full HMI-9 medium added to 1×10^7 (A) or 1.5×10^7 (B) T. brucei brucei in 1 ml of full HMI-9 medium being monitored at 750 nm. Conditions from t = 0 min: a, 10 μM melarsen oxide; b, 10 μM melarsen oxide plus 1 μM pentamidine; c, 0.5 μM phenylarsine oxide; d, 0.5 μM phenylarsine oxide plus 1 μM pentamidine; e, control, no drug. Dotted lines indicate the incubations in the presence of 1 μM pentamidine.
led to substantial melarsoprol resistance in vitro (Shahi et al., 2002) but not in vivo, and TbMRPA overexpression was not observed in melarsoprol-resistant clinical isolates from a number of patients with sleeping sickness (Alibu et al., 2006).

Thus, although resistance based on target modifications or active efflux cannot be excluded, the available information is consistent with changes to drug entry being the cause of arsenical and diamidine resistance in African trypanosomes. Our findings, using pentamidine-adapted laboratory strains, are strongly in agreement with this hypothesis. We identify HAPT1 as potentially a key drug resistance determinant and for the first time provide a biochemical model for high-level arsenical-diamidine cross-resistance in African trypanosomes.

High-Level Pentamidine Resistance Is Associated with Loss of HAPT1 but Not of LAPT1 Activity. Several independent lines of evidence suggested that the pentamidine-adapted lines KO-B48 and KO-D48 had lost HAPT1 rather than LAPT1 activity. Because the adaptation started with the tbat1+/− clonal line, P2 transport activity was also not present. We have shown previously that propamidine is an inhibitor of high-affinity pentamidine transport in T. brucei but not of the low-affinity transport component (De Koning, 2001b), and the increase in propamidine resistance is certainly consistent with loss of HAPT1 activity. Furthermore, there was no increased resistance to diminazene aceturate, which is transported only by TbAT1/P2 (De Koning et al., 2004), or to phenylarsine oxide, which diffuses across membranes.

The resistance profiles and [3H]pentamidine transport rates of the two adapted lines were highly similar. These experiments measured initial rates of pentamidine uptake rather than accumulation, and the results can only be explained in terms of deficient uptake rather than active extrusion or intracellular sequestration. Unlike T. brucei brucei s427 and tbat1+/− (De Koning, 2001b; Matovu et al., 2003), transport of 15 nM [3H]pentamidine in KO-B48 was not inhibited by submicromolar concentrations of unlabeled pentamidine, saturated only by very high levels of the substrate, and $K_m$ and $V_{max}$ values were identical to those reported earlier for LAPT1 (De Koning, 2001b).

In tbat1+/−, lysis induced by melarsen oxide was very considerably delayed, relative to T. brucei brucei s427, by coadministration of as little as 1 μM pentamidine—sufficient to saturate HAPT1 but not LAPT1. Pentamidine was apparently competing with the arsenical drug for transporter-mediated import, because 1 μM of pentamidine had no effect on the rapid lysis induced by phenylarsine oxide. These experiments clearly demonstrate the uptake of melarsen oxide through HAPT1. The same process was assessed by monitor-

**Fig. 7.** Assessment of DAPI uptake using fluorescent microscopy over time. LS bloodstream forms of WT s427, tbat1+/− and KO-B48 were incubated with 10 μM DAPI and fluorescence was observed under an Axioplan 2 imaging microscope ($\lambda_{ex} = 365$ nm, $\lambda_{em} = 445$ nm) at 1000× magnification.

**Fig. 8.** DAPI fluorescence acquisition in live KO-B48 cells incubated in the absence or presence of a low (10 μM) or high (1 mM) concentration of pentamidine, or 50 μM verapamil over time (A). Separate images (DIC, DAPI, and combined overlay) from glutaraldehyde-fixed parasites after 60-min incubation with DAPI in the presence or absence of pentamidine (B). DAPI concentration was 10 μM. Magnification was 1000×. Comb, combined overlay.

**Fig. 9.** TbMRPA expression in various Trypanosoma brucei brucei lines. Western blots with extracts of tbat1+/− (lane 1), KO-B48 (lane 2), NY-mrpa+ (lane 3), NY-mrpa− (lane 4), and NY (lane 5), using anti-TbMRPA (A) or PFR antisera (B).
ing DAPI fluorescence as a marker for diamidine accumulation. Scant difference was observed between the WT and \( \text{tbat}1^{-/-} \) lines, but the development of fluorescence was substantially delayed in KO-B48 cells (Fig. 7), indicating a loss of diamidine transport unrelated to TbAT1/P2. The remaining DAPI transport activity was saturated by 1 mM but not by 10 \( \mu \text{M} \) pentamidine, consistent with uptake through LAPT1 rather than HAPT1.

**The Role of HAPT1 in Accumulation of Melanimophenyl Arsenicals.** Since the seminal observations of Carter and Fairlamb (1993) that a \( T. \text{brucei brucei} \) line adapted to high levels of resistance to melanimophenyl arsenicals had lost activity of a transporter they named P2, much evidence has accumulated linking TbAT1/P2 to arsenical resistance (Carter et al., 1999; Delespaux and De Koning, 2006). Loss of P2 activity alone was not sufficient to establish substantial arsenical resistance as the \( \text{tbat}1^{-/-} \) line was less than 3-fold resistant to melarsen oxide and melarsoprol (Matovu et al., 2003). We show here that lysis of trypanosomes induced by melanimophenyl arsenicals, but not by phenylarsine oxide, was 1) sensitive to inhibition by 1 \( \mu \text{M} \) pentamidine and 2) much delayed in KO-B48 cells. The level of resistance to melarsen oxide reached 15-fold in KO-B48. We conclude that high levels of arsenical resistance can be induced by selection with pentamidine and can be achieved by the sequential loss of TbAT1 and HAPT1. The example with \( T. \text{brucei gambiense} \) 386Mr shows that selection with melanimophenyl arsenicals can likewise lead to loss of the same two transporters, thus explaining reported incidences of pentamidine/arsenical cross-resistance (Frommel and Balber, 1987; Kaminsky and Mäser, 2000). High levels of resistance could be far more easily induced when starting from a TbAT1-null background. This is potentially significant given the increasing levels of resistance to melarsoprol and diminazene aceturate in the field, believed to be at least partially linked to loss of TbAT1/P2 activity in the resistant strains (Kaminsky and Mäser, 2000; De Koning et al., 2004; Delespaux and De Koning, 2006).

It must be acknowledged that our findings have been generated under laboratory conditions and that any clinical link between loss of HAPT and diamidine or melarsoprol treatment failure remains theoretical. However, the previous explanation for the observed treatment failures (loss of TbAT1/P2 only) proved unsatisfactory (Matovu et al., 2003), and we here propose an improved model that can now be tested against the situation in the field. Efforts to identify the genes encoding HAPT and LAPT are ongoing and would greatly assist the evaluation of this model against clinical isolates.

It is possible that additional mechanisms of resistance to melanimophenyl arsenicals may exist, because cross-resistance is not always observed (e.g., Fairlamb et al., 1992). However, conclusions based on a review of the literature are complicated by differences in technique (e.g., in vitro or in vivo assessment of resistance), variations in drugs tested, and other confounding factors.
The Role of Drug Efflux: ABC Transporters. It has been demonstrated that overexpression of the T. brucei brucei ABC transporter MRPA resulted in a 10-fold resistance to melarsoprol in vitro (Shahi et al., 2002), an effect that was additive with the effect of TbaT1 deletion (Lüsch et al., 2006). However, we found no detectable levels of TbMRPA in the two pentamidine-adapted lines. In addition, we found that the P-glycoprotein inhibitor verapamil had no effect on DAPI accumulation, and thus we have been unable to find evidence that the increased resistance phenotype is the result of increased activity of P-glycoprotein or mdr-type ABC transporters.

Is Pentamidine Resistance Associated with Reduced Virulence? Pentamidine is still the first-line drug for early-stage gambiense sleeping sickness. Treatment failures are rare but stable over at least three decades (Pépin and Milord, 1994). In contrast, pentamidine resistance seems to emerge easily in Leishmania species (Papadopoulou et al., 1998), though pentamidine usage against leishmaniasis has been very much less widespread than against African trypanosomiasis. The difference can be explained in part by the involvement of an mdr-type ABC transporter in pentamidine efflux from Leishmania (Coelho et al., 2003) and the fact that pentamidine uptake in Leishmania is apparently mediated by a single transporter (Basselin et al., 2002; Bray et al., 2003). The presence of three pentamidine transporters in T. brucei brucei has been argued to be responsible for the lack of clinical resistance to pentamidine (Bray et al., 2003). However, it has been demonstrated that trypanosomes with defective tbat1 genes can be isolated from sleeping sickness patients (Matovu et al., 2001), and we show here that the further loss of just HAPT1 leads to very significant levels of pentamidine resistance. The presence of multiple accumulation routes alone may thus not be sufficient to prevent the occurrence of resistance. One explanation would be loss of viability or virulence in the resistant parasites. Berger et al. (1995) reported that pentamidine adapted T. brucei brucei clone PR32.6 was far less virulent than the parental strain and excluded increased susceptibility to the host’s immune system or changes attributable to prolonged cultivating as factors. The phenotype of the KO-B48 and KO-D48 lines seems identical to that of PR32.6. These lines were less infective in mice and rats than the parental line, which had been cultured at least equally long, and immunosuppression of the animals did not lead to substantially higher parasitaemia. There is thus a distinct possibility that high-level pentamidine resistance is not viable in the field, and self-limiting.

Acknowledgments

We are grateful to Professor Mike Turner for the use of T. brucei gambiense strains 386Ms and 386Mr and to Professor Christine Clayton for the gift of anti-TbMRPA antiserum. We are particularly grateful to Professor Paul Voorheis (University of Dublin) for expert advice and assistance on the preparation of plasma membrane protein-enriched fractions for Western blotting.

References


Downloaded from multipharm.aspertjournals.org at ASJET Journals on June 22, 2017.


**Address correspondence to:** Dr. Harry P. de Koning, Institute of Biomedical and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, United Kingdom. E-mail: h.de-koning@bio.gla.ac.uk